IACP to Participate on American Academy of Ophthalmology Panel
IACP's Sarah R. Dodge-Palmer – Vice President of Government Affairs, and IACP Member Charles Leiter, PharmD, Leiter's Compounding Pharmacy in San Jose, Calif., will serve on a panel today, April 12, 2013, at the American Academy of Ophthalmology’s Mid-Year Forum hearing on compounded pharmacies.
Hearing #2. The Confounding Situation with Compounded Drugs: The Risks and Impact for Ophthalmology
Moderator: George A. Williams, MD – Consultant, Health Policy Committee, American Academy of Ophthalmology therapeutic use of compounded drugs is critical to the management of blinding and other significant eye diseases for patients off all ages. Recent events have raised substantial risks and obstacles associated with obtaining and providing these necessary drugs. This hearing will discuss the legal, clinical and regulatory environment that will impact ophthalmology’s use of compounded drugs.
10:15 am – 10:20 am Introduction
George A. Williams, MD – Consultant, Health Policy Committee, American Academy of Ophthalmology
10:20 am – 10:35 am Compounding for Ophthalmology – the Clinical Perspective
Suber S. Huang MD, MBA – Chair, Research, Regulatory, and External Scientific Affairs Committee, American
Academy of Ophthalmology
10:35 am – 10:50 am The Pharmacy Perspective
Charles Leiter, PharmD – President, Leiter’s Compounding Pharmacy
Sarah R. Dodge-Palmer – Vice President of Government Affairs, International Academy of Compounding Pharmacists
10:50 am – 11:05 am Using Compounded Products – Liability Issues for Clinicians
Paul Weber, JD – Vice President of Risk Management-Legal, Ophthalmic Mutual Insurance Company (OMIC)
11:05 am – 11:45 am Q&A
Questions to Consider